Volume 122, Issue 2 , Pages 162.e1-162.e9, February 2009
“Dose-dependent” Impact of Recurrent Cardiac Events on Mortality in Patients with Heart Failure
Abstract
Background
The mortality impact of recurrent cardiac hospitalizations has not been delineated in community-based heart failure patients. We determined if a “dose-dependent” relationship exists between heart failure events and death, accounting for temporal changes in age, comorbidities, and disease severity.
Methods
Among heart failure patients in the Enhanced Feedback For Effective Cardiac Treatment Study with onset between April 1999 and March 2001, we compared long-term survival (until March 2006) in those with recurrent heart failure or cardiovascular events, relative to those free of such events.
Results
In 9138 patients, 28,442 person-years of follow-up were examined (mean age: 75.3 years, 49.6% male). Recurrent heart failure events occurred 1, 2, 3, and ≥4 times in 2352 (25.7%), 1020 (11.2%), 505 (5.5%), and 596 (6.5%) patients, respectively. Cardiovascular readmissions occurred 1, 2, 3, and ≥4 times in 2522 (27.6%), 1509 (16.5%), 975 (10.7%), and 1672 (18.3%) patients, respectively. Compared with those without recurrent heart failure events, the adjusted relative mortality rates for 1, 2, 3, and ≥4 heart failure events were 2.41 (95% confidence interval [CI], 2.24-2.60), 3.00 (95% CI 2.72-3.32), 4.00 (95% CI, 3.51-4.56), and 5.16 (95% CI, 4.55-5.85), respectively. Compared with those without cardiovascular events, the adjusted relative mortality rates for 1, 2, 3, and ≥4 cardiovascular events were 3.33 (95% CI, 3.05-3.63), 4.61 (95% CI, 4.16-5.10), 6.29 (95% CI, 5.59-7.07), and 8.95 (95% CI, 8.05-9.95), respectively.
Conclusions
The risk of death increases progressively and independently with each heart failure or cardiovascular event. The number of prior events predicts mortality and should be ascertained in patients with heart failure.
Keywords: heart failure, hospitalizations, mortality, outcomes research, prognosis
To access this article, please choose from the options below
Funding: This research was supported by a Canadian Institutes of Health Research (CIHR) grant and a CIHR Team Grant in Cardiovascular Outcomes Research, a clinician-scientist (DSL) and new investigator award (PCA) from the CIHR, career investigator awards from the Heart and Stroke Foundation of Ontario (JVT, DAA), and a Canada Research Chair in health services research (JVT).
Conflict of Interest: The authors have no conflict of interest to disclose.
Authorship: All co-authors had access to the data and contributed to the manuscript.
PII: S0002-9343(08)00958-3
doi:10.1016/j.amjmed.2008.08.026
© 2009 Elsevier Inc. All rights reserved.
Volume 122, Issue 2 , Pages 162.e1-162.e9, February 2009

